Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Non-executive director to bring extensive life science industry and finance experience

Vaxart Appoints W. Mark Watson to its Board of Directors

All six proposals approved in the 2022 Proxy Statement

Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4

Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.

Could This Unknown Stock Beat Moderna in 2023?

Conference call to begin at 4:30 p.m. ET Conference call to begin at 4:30 p.m. ET

Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8

Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass

Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET

Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples

Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) --  Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scientist, each will present data from the company's COVID-19 oral tablet vaccine development program at the International Congress of Mucosal Immunology 2022, which is being held in Seattle July 16 to 20, 2022.

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

Key Proposal #2 has received significant support, but additional votes are needed for approval

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

Model will be used in Vaxart's Phase II Omicron Challenge Trial

Vaxart Announces Agreement with hVIVO to Develop World's First Human Omicron Challenge Model

Management to discuss progress on its programs, annual stockholders' meeting proposals

Vaxart to Host Investor Q&A Webcast

AstraZeneca

GlaxoSmithKline

Novartis

Sanofi

It depends on which subsector you're talking about.

What Could a Recession Mean for Healthcare Stocks?

Meeting adjourned to July 6, 2022 at 9:30 a.m. PT

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Novavax

Both face significant risks in the coming quarters.

Better Buy: Novavax vs. Vaxart

Results provide additional support for the cross-reactivity of Vaxart's oral vaccine candidates

New Preclinical Data Demonstrate Two of Vaxart's COVID-19 Vaccine Candidates Protect Against Omicron

Inovio Pharmaceuticals

Stock Market Plunge: 2 Stocks to Avoid Right Now

Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Amazon

Target

Vertex Pharmaceuticals

The stock market offers plenty of opportunities -- even during difficult times.

Market Dip: Here's How to Invest Safely

A preclinical study in hamsters showed both a decrease in infectious  virus and in transmission

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Aurora Cannabis

Redfin

Select analysts foresee these once-popular stocks delivering huge gains for shareholders.

These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall Street

The company still is far from the vaccine race finish line.

Can This 1 Thing Hurt Vaxart?

Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

Bed Bath & Beyond

Netflix

Here are three stocks that have analysts running for the exit due to their declining or risky market prospects The post 3 Stocks That Have Analysts Running for the Exit appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.

3 Stocks That Have Analysts Running for the Exit

These two companies have been left in the dust. Is it too late for them?

2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.

Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

Moderna

Their products could deliver major revenue over time.

News for Vaxart Stock (VXRT)